MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial – Nature

1. MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial  Nature
2. New T-cell engager shows promise for advanced solid tumors  Medical Xpress
3. Breakthrough in cancer immunotherapy:…

Continue Reading

News Source: news.google.com